Melanoma Clinical Trial

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Summary

Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.

View Full Description

Full Description

The phase 1b part is an open-label, multicenter, single-arm study where all participants will receive talimogene laherparepvec in combination with ipilimumab.

The phase 2 part of the study is an open-label, multicenter, randomized study to further assess the safety and to evaluate the efficacy of talimogene laherparepvec in combination with ipilimumab. Participants will be randomized 1:1 to receive talimogene laherparepvec plus ipilimumab or ipilimumab alone.

Participants randomized before amendment 2 will be stratified by stage of disease (stage IIIB/C, IVM1a, and stage IVM1b vs IVM1c) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E (a mutation resulting in a substitution of glutamic acid for valine at codon 600) (mutation vs mutation not present). Participants randomized after amendment 2 will be stratified by stage of disease (stage IIIB/C and IVM1a vs stage IVM1b and IVM1c) and prior therapy (treatment naïve vs previously treated with systemic anticancer immunotherapy vs previously treated with systemic anticancer treatment other than immunotherapy).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed diagnosis of malignant melanoma.
Stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c disease that is not suitable for surgical resection
Phase1: Treatment naïve: Must not have received any prior systemic anticancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy for unresected stage IIIB to IV melanoma.

Phase 2:

Either treatment naïve or received only one line of systemic anticancer therapy if v-raf murine sarcoma viral oncogene homolog B1 (BRAF) wild-type or up to two lines of systemic anticancer therapy including one BRAF inhibitor-containing regimen if BRAF mutant. Treatments given in an adjuvant setting (eg, interferon, radiotherapy, isolated limb perfusion, or investigational agents) are not considered as prior lines of therapy. No prior talimogene laherparepvec, other oncolytic virus therapies, or tumor vaccines are allowed, even if given in the adjuvant setting.
Subjects treated with prior ipilimumab must have had partial response (PR), complete response (CR), or at least 6 months of stable disease followed by disease progression.
Subjects previously treated with anti-program death-1 (PD1) or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least 28 days prior to randomization.

Measurable disease defined as one or both of the following

at least 1 melanoma lesion that can be accurately and serially measured in at least 2 dimensions and for which the longest diameter is ≥ 10 mm and with perpendicular diameter ≥ 5 mm as measured by contrast-enhanced or spiral computed tomography (CT) scan for visceral or nodal/soft tissue disease. Lymph nodes must measure > 15 mm in their short axis to be considered measurable by CT scan.
at least 1 superficial cutaneous or subcutaneous melanoma lesion that can be accurately and serially measured in at least 2 dimensions and for which the short axis is ≥ 5 mm as measured by calipers

Injectable disease (ie, suitable for direct injection or through the use of ultrasound [US] guidance) defined as follows:

at least 1 injectable cutaneous, subcutaneous, or nodal melanoma lesion ≥ 5 mm in longest diameter
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate hematologic, hepatic, renal, and coagulation functions

Exclusion Criteria:

Primary uveal or mucosal melanoma
History or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia)
Phase 1b: History or evidence of central nervous system (CNS) metastases
Phase 2: Clinically active cerebral melanoma metastases. Subjects with up to 3 cerebral metastases, and neurological performance status of 0 may be enrolled, provided that all lesions have been adequately treated with stereotactic radiation therapy, craniotomy, or Gamma knife therapy, with no evidence of progression, and have not required steroids, for at least 2 months prior to enrollment.
History or evidence of symptomatic autoimmune disease (such as pneumonitis, glomerulonephritis, vasculitis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, scleroderma, or other), or history of autoimmune disease that required systemic treatment (ie, use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) in past 2 months prior to enrollment. Replacement therapy (eg, thyroxine for hypothyroidism, insulin for diabetes mellitus) is not considered a form of systemic treatment for autoimmune disease.
History of or plan for splenectomy or splenic irradiation
Active herpetic skin lesions or prior complications of herpes simplex type-1 virus (HSV-1) infection (eg, herpetic keratitis or encephalitis).
Requires intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use
Known human immunodeficiency virus (HIV) disease
Known acute or chronic hepatitis B or hepatitis C infection
Phase 1b: Prior talimogene laherparepvec, ipilimumab, other CTLA-4 inhibitors, PD-1 inhibitors, or tumor vaccine
Phase 2: Prior talimogene laherparepvec, other oncolytic virus therapies, or tumor vaccines
Currently receiving or less than 28 days since ending systemic anticancer treatment for unresected stage IIIB to IV melanoma

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

217

Study ID:

NCT01740297

Recruitment Status:

Completed

Sponsor:

Amgen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 40 Locations for this study

See Locations Near You

Research Site
Tucson Arizona, 85724, United States
Research Site
Beverly Hills California, 90211, United States
Research Site
Los Angeles California, 90025, United States
Research Site
Los Angeles California, 90089, United States
Research Site
Los Angeles California, 90095, United States
Research Site
San Francisco California, 94115, United States
Research Site
Santa Rosa California, 95403, United States
Research Site
Aurora Colorado, 80045, United States
Research Site
Jacksonville Florida, 32207, United States
Research Site
Jacksonville Florida, 32224, United States
Research Site
Lakeland Florida, 33805, United States
Research Site
Miami Florida, 33140, United States
Research Site
Chicago Illinois, 60612, United States
Research Site
Indianapolis Indiana, 46202, United States
Research Site
Indianapolis Indiana, 46260, United States
Research Site
Iowa City Iowa, 52242, United States
Research Site
Louisville Kentucky, 40202, United States
Research Site
Minneapolis Minnesota, 55407, United States
Research Site
Saint Louis Missouri, 63110, United States
Research Site
Morristown New Jersey, 07962, United States
Research Site
New Brunswick New Jersey, 08903, United States
Research Site
New York New York, 10029, United States
Research Site
New York New York, 10032, United States
Research Site
Chapel Hill North Carolina, 27599, United States
Research Site
Canton Ohio, 44718, United States
Research Site
Cincinnati Ohio, 45267, United States
Research Site
Charleston South Carolina, 29425, United States
Research Site
Nashville Tennessee, 37232, United States
Research Site
Houston Texas, 77030, United States
Research Site
Salt Lake City Utah, 84112, United States
Research Site
Richmond Virginia, 23298, United States
Research Site
Milwaukee Wisconsin, 53226, United States
Research Site
Bordeaux , 33075, France
Research Site
Grenoble Cedex 9 , 38043, France
Research Site
Lille , 59037, France
Research Site
Nantes Cedex 1 , 44093, France
Research Site
Paris , 75010, France
Research Site
Göttingen , 37075, Germany
Research Site
Kiel , 24105, Germany
Research Site
Tübingen , 72076, Germany

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

217

Study ID:

NCT01740297

Recruitment Status:

Completed

Sponsor:


Amgen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider